Geron Corp - GERN STOCK NEWS

Geron Corporation (NASDAQ: GERN) announced that data from the pivotal IMerge Phase 3 clinical trial of its telomerase inhibitor, imetelstat, in lower-risk myelodysplastic syndromes (MDS) is scheduled for oral presentation at the 2023 ASCO Annual Meeting in Chicago. The study evaluates imetelstat in patients who are transfusion dependent and have relapsed or are refractory to erythropoiesis-stimulating agents. The primary efficacy endpoint is the rate of red blood cell transfusion independence lasting at least eight weeks, with secondary endpoints focusing on longer durations and hematologic improvement. The trial enrolled 178 patients across multiple regions. Geron plans to submit a New Drug Application in mid-2023 and a Marketing Authorization Application in the EU later this year.

Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options to acquire 1,684,220 shares of common stock as an employment inducement for newly hired employees. The options were issued on April 19, 2023, at an exercise price of $2.49 per share, equal to the stock's closing price that day. Of the total, 1,586,000 options have a 10-year term and vest over four years, with an initial 12.5% vesting after six months. The remaining shares will vest monthly over the following 42 months. The remaining 98,220 options will vest upon achieving specific regulatory milestones. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and follows Geron’s 2018 Inducement Award Plan.

Geron focuses on therapies for hematologic malignancies, particularly its investigational telomerase inhibitor, imetelstat.

Geron Corporation (Nasdaq: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that John A. Scarlett, M.D., the Chairman and CEO, will participate in fireside chats at two upcoming investor conferences.

• 22nd Annual Needham Virtual Healthcare Conference
  Date: April 20, 2023
  Time: 10:15 a.m. ET
• Stifel 2023 Virtual Targeted Oncology Days
  Date: April 25, 2023
  Time: 2:00 p.m. ET

Webcasts of the chats will be accessible via the Investor Relations section of Geron’s website and archived for 30 days post-event. Geron is advancing its first-in-class telomerase inhibitor, imetelstat, which aims to impact the treatment of these diseases significantly.

Geron Corporation (Nasdaq: GERN) announced the granting of non-statutory stock options for 490,630 shares of its common stock as an inducement to newly hired employees. These options were issued on March 15, 2023, at an exercise price of $2.62 per share. Of the total options, 460,000 shares will vest over four years, while 30,630 shares will vest upon achieving regulatory milestones. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan, supporting the recruitment of talent crucial for advancing its hematologic malignancy treatments.

Geron Corporation (Nasdaq: GERN) provided updates on its lead product, imetelstat, and its financial performance for Q4 2022 and the full year. The company reported a net loss of $42.6 million for Q4 and $141.9 million for the year, with revenues of $103,000 and $596,000, respectively. In January 2023, Geron raised $213.3 million through an underwritten public offering. Positive Phase 3 results for imetelstat in lower-risk myelodysplastic syndromes (MDS) have set the stage for planned NDA and MAA submissions in 2023, with potential U.S. commercial launch expected in 2024. The company also intends to grow its workforce to support these initiatives.

Geron Corporation (Nasdaq: GERN) announced it will release its Q4 and full-year 2022 financial results post-market on March 16, 2023. A conference call will follow at 4:30 p.m. ET to discuss these results and future milestones. The press release will be accessible on their website.

Geron is focused on developing therapies for hematologic malignancies with its investigational telomerase inhibitor, imetelstat, which aims to change the course of these diseases.

Geron Corporation (NASDAQ: GERN) announced the grant of non-statutory stock options for 640,550 shares of common stock to new employees. The stock options were issued on February 15, 2023, at an exercise price of $2.69 per share, matching Geron's closing price on that date. Of the options, 595,800 shares will vest over four years, while 44,750 shares are contingent on achieving specific regulatory milestones. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan. The company focuses on therapies for hematologic malignancies.

Geron Corporation (NASDAQ: GERN) announced the granting of non-statutory stock options to a newly hired employee, totaling 75,730 shares. The options were issued on January 18, 2023, at an exercise price of $3.12 per share, matching the stock's closing price on the grant date. Of these, 70,000 shares have a 10-year term, vesting over four years with an initial 12.5% vesting at six months. The remaining 5,730 shares vest upon achieving certain regulatory milestones. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron’s 2018 Inducement Award Plan.